CONNAUGHT HOUSE, DUBLIN 4, L2
Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Announces Appointment of Anne C. Whitaker to Board of Directors
Amendment to Credit Agreement - Alkermes Enters Term Loan Facilities
Amended material disclosure
Financial Results, Press Release
Termination of Authorized Generic Product Supply Agreement with Amneal
Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Shareholders Approve Increase of 5.9M Shares in 2018 Stock Option Plan
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
S-8 POS